Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Jounce Therapeutics

Jounce Therapeutics
2012 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
JNCE STOCK SYMBOL
$4.43 SHARE PRICE (As of Tuesday Closing)
Description

Jounce Therapeutics Inc is a clinical stage immunotherapy company. The company is dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company's strategy is to create immunotherapies targeting a variety of the diverse cellular components of the immune system, as well as non-immune cells resident within the tumor, all of which can vary greatly among tumors within and across indications. This may provide benefit to patients with tumors across the spectrum from highly inflamed, or hot, to poorly inflamed, or cold, and especially those not well served by current therapies. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody.

Ownership Status
Publicly Held
Financing Status
Failed Transaction (M&A)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 780 Memorial Drive
  • Cambridge, MA 02138
  • United States

+1 (857) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Jounce Therapeutics’s full profile, request a free trial.

Jounce Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.66 - $8.58 $146M $4.47 -$0.84 130K 33M

Jounce Therapeutics Financials Summary

In Thousands,
USD
TTM
31-Dec-2018
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value (101,558) (125,451) 400,913
Revenue 65,201 65,201 71,644 37,197
EBITDA (23,502) (23,502) (11,985) (11,759)
Net Income (27,379) (27,379) (16,443) (13,703)
Total Assets 214,452 214,452 296,660 271,312
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Jounce Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Jounce Therapeutics‘s full profile, request access.

Request full access to PitchBook

Jounce Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Jounce Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Jounce Therapeutics Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rigontec Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000000 Private Equity-Backed McLean, VA 00 000.00 000000000. 0 000.00
To view this company’s complete list of competitors, request access »

Jounce Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Jounce Therapeutics‘s full profile, request access.

Request full access to PitchBook

Jounce Therapeutics Executive Team (19)

Name Title Board
Seat
Contact
Info
Richard Murray Ph.D Chief Executive Officer, President & Board Member
Stephen Farrand Ph.D Chief Technology Officer
Deborah Law Chief Scientific Officer
Hugh Cole Chief Business Officer & Head, Corporate Development
Jennifer Michaelson Ph.D Executive Program Leader & Senior Director of Pharmacology and Preclinical Development

4 Former Executives

You’re viewing 5 of 19 executives. Get the full list »

Jounce Therapeutics Board Members (7)

Name Representing Role Since Contact
Info
Barbara Duncan Jounce Therapeutics Board Member 000 0000
Cary Pfeffer MD Third Rock Ventures Board Member 000 0000
Higgons Duncan Self Board Member 000 0000
Perry Karsen Third Rock Ventures Chairman 000 0000
Richard Murray Ph.D Jounce Therapeutics Chief Executive Officer, President & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »